Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPT Duration and Ticagrelor After Bridge Stenting
NCT06301776Recruiting
- Sponsor
- The Fourth Hospital of China Medical University
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ticagrelor in Vertebral artery stenosis (VBI) (2 arms), sponsored by The Fourth Hospital of China Medical University. Primary endpoint: Incidence of the composite endpoint of non-fatal ischaemic Stroke, TIA, and all-cause mortality at 12 months. Started Dec 2023; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
Vertebral artery stenosis (VBI)
Beyond the preview
Go deeper on NCT06301776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06301776.